Sweden's first unit for preclinical metabolomics studies inaugurated in Uppsala

In September 2025, SciLifeLab's Drug Discovery and Development platform (DDD) and SFO-Committee UU are launching Sweden's first dedicated capability for studies of pharmaco-metabolomics during the preclinical stage of drug discovery and development. With the environment, that has its geographical home at Uppsala Biomedical Center, initiators Pawel Baranczewski and Daniel Globisch aim to strengthen our nation’s drug discovery environment.

“Our primary objective is to investigate drug-induced metabolomic changes, which makes our unit an important complement to SciLifeLab's existing resources. We primarily support academic research groups and spin-offs, and in the autumn we will present our activities to, among others, SciLifeLab DDD project teams, Chemical Biology and Genomic Engineering and academic research groups that we believe will greatly benefit from our service,” says Pawel Baranczewski, Associate Professor at Uppsala University.

The new capability combines the expertise of ADMEoT Unit (UDOPP) at SciLifeLab DDD and the Globisch laboratory - two central arenas for preclinical drug discovery and development, Chemical Biology, Bioorganic Chemistry and Metabolomics. Recruitment of two specialists with operational duties is currently underway.

“In Sweden, there are platforms for clinical metabolomics studies, and by adding support in the preclinical phase, we can offer more coherent support all the way from laboratory towards candidate drugs selection and in long-term to new approved drugs. We now welcome applications, and the great interest we are meeting confirms that our unit will add important values ​​to both ongoing and future drug discovery projects,” states Daniel Globisch, Professor of Analytical chemistry.

text: Magnus Alsne, photo: Mikael Wallerstedt a o